Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
- Sarcoidosis SFN: 4 mg SC daily for 28 days (optimal dose per Phase 2b).
- Pilot study: 2 mg IV three times weekly for 4 weeks.
Dose evidence detail — Cibinetide (ARA-290)
Detailed dose evidence documented for Cibinetide (ARA-290) in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Not established
No approved labeled regimen
No established or recommended human dose.
- None.
Not established
What is not established
- No established or recommended human dose. Phase 3 dose confirmation is pending.
Cibinetide (ARA-290) — Monographie-Abschnitt zu Dosis und Anwendung